Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Tesaro Inc.

2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of Cancer


Release Date: March 30, 2018
Expiration Date: March 30, 2019
Media: Internet - based

 

Activity Overview

Immunotherapy options for patients with cancer are increasing rapidly, shaping the treatment landscape for patients with a variety of different malignancies. This online activity features an expert panel of oncologists who will discuss recent advancements in the field of immunotherapy, highlighting noteworthy data presented at major society meetings in 2017. Each module will focus on a different component of immunotherapy and its growing impact in cancer care. Topics will include advancements in the understanding of immunotherapy mechanisms and tumor biology, the exploration of prognostic markers to personalize immunotherapy utilization, an analysis of key safety and efficacy data from recent clinical trials of immunotherapy, and a look ahead at ongoing immunotherapy studies for patients with cancer.

Our panel of experts will provide clinical insight into the implications of recent immunotherapy-related data, review the potential application of these data, and discuss the future direction of immunotherapy strategies for patients with cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, and Tesaro Inc.

CME Activity Table of Contents

  • Welcome and Introductions
  • Module 1: Biology and Mechanisms of Immunotherapy Agents
  • Module 2: Personalizing Care – Evolving Evidence on Biomarkers
  • Module 3: Current Strategies and Key Study Data
  • Module 4: Emerging Combinations and Next Steps in Clinical Trials
  • Summary and Closing Remarks

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Evaluate the latest data regarding mechanisms of immunotherapeutic strategies as they apply to solid and liquid malignancies and emerging biomarkers guiding the optimal selection of patients
  • Review efficacy and safety data for immunotherapeutic approaches across multiple malignancies and patient types
  • Describe key clinical issues regarding the application of immune checkpoint inhibitors and summarize ongoing associated clinical trials
  • Determine the occurrence and methods to mitigate the impact of immune-related adverse events based on recent clinical trial evidence

Faculty, Staff, and Planners' Disclosures

Faculty

Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosure: Consultant: Roche, AstraZeneca, Novartis, Merck, Lilly, Bristol-Myers Squibb, Pfizer, Gritstone Oncology, ARMO Biosciences

Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
University of California, San Diego
Associate Director for Translational Science, Moores Cancer Center
Director, Cancer Immunotherapy, Moores Cancer Center
Co-Leader, Solid Tumor Therapeutics Program
Co-Director, Head and Neck Cancer Center of Excellence
San Diego, CA

Disclosure: Research Grants: AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Liquid Genomics, Merck, Mirati, Novartis, Peregrine, Pfizer, Roche Diagnostics, Synta, Trovagene

Susan F. Slovin, MD, PhD
Attending Physician
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: No relevant financial relationships with commercial interests to disclose.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By